Radiotherapy clinical trials at UCSF

1 in progress, 0 open to eligible people

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Sorry, in progress, not accepting new patients
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco 5391959, California 5332921 and other locations

Last updated: October 23, 2025